NK-Exo, when engineered with both IL24 and NKG2D, exhibit enhanced tumor selectivity and killability due to the tumor-specific properties of IL24 and the ability of NKG2D to target highly overexpressed ligands on tumor cells, making NK-Exos a more effective and safer therapeutic alternative. This evidence concerns the gene KLRK1 and neoplasm.